¹û¶³ÊÓƵ

We are happy to announce the arrival of Ruth Bateson as Senior Director, Clinical Operations and Charlotte Chorley as Communications Lead.

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials ¹û¶³ÊÓƵ aims to track and improve patient experience through an integrated, digitally-assisted treatment model

Partnership will capture behavioural and physiological signals and predictive biomarkers in ¹û¶³ÊÓƵ’s upcoming Phase 2 clinical trials. New digital strategy aims to improve patient outcomes and safety by integrating advanced digital tools into the psychedelic treatment journey.

¹û¶³ÊÓƵ to collaborate with Lophora on researching New Clinical Entities (NCE’s) Broad collaboration with Lophora will further strengthen ¹û¶³ÊÓƵ’s world class management and R&D team

¹û¶³ÊÓƵ Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the 8th Annual LSX World Congress 2022.

Study represents continued efforts to further understand the clinical and pharmacological potential of 5-MeO-DMT. BPL-003 is ¹û¶³ÊÓƵ’s innovative dry powder intranasal formulation of 5-MeO-DMT using FDA approved intranasal delivery devices. Data from Phase 1 will be used to select lead compound for upcoming Phase 2 in treatment resistant depression (TRD).

¹û¶³ÊÓƵ Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the 32nd Annual Oppenheimer Healthcare Conference

Literature review highlights need for further clinical exploration of 5-MeO-DMT

Training programme to be conducted in partnership with industry-leading educational company, Fluence. Initiation of training represents key step to incorporate psychedelic-assisted psychotherapy to deliver potentially clinically meaningful improvements.

B Corporations represent a new kind of business philosophy to protect and develop the future of all stakeholders.